TK, C., M, E., R, M., U, D. G., T, B., NS, B., . . . CG, P. (2023). Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study. The Lancet. Oncology, 24(3), 228. https://doi.org/10.1016/S1470-2045(23)00049-9
Παραπομπή σε μορφή Chicago (17η εκδ.)TK, Choueiri, et al. "Lenvatinib Plus Pembrolizumab Versus Sunitinib as First-line Treatment of Patients with Advanced Renal Cell Carcinoma (CLEAR): Extended Follow-up from the Phase 3, Randomised, Open-label Study." The Lancet. Oncology 24, no. 3 (2023): 228. https://doi.org/10.1016/S1470-2045(23)00049-9.
Παραπομπή σε μορφή MLA (9th εκδ.)TK, Choueiri, et al. "Lenvatinib Plus Pembrolizumab Versus Sunitinib as First-line Treatment of Patients with Advanced Renal Cell Carcinoma (CLEAR): Extended Follow-up from the Phase 3, Randomised, Open-label Study." The Lancet. Oncology, vol. 24, no. 3, 2023, p. 228, https://doi.org/10.1016/S1470-2045(23)00049-9.